-
AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment
•
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (NASDAQ: AZN) PD-L1 inhibitor Imfinzi (durvalumab) for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for adults with muscle-invasive bladder cancer (MIBC). Clinical Trial ResultsThe approval is supported…
-
AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment
•
UK pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving another indication approval from China’s National Medical Products Administration (NMPA) for its Calquence (acalabrutinib). The drug is now approved for use in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as a monotherapy. This marks the third…
-
AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China
•
UK-based pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has announced the official market launch of its monoclonal antibody Fasenra (benralizumab) in China. The drug is approved as a maintenance therapy for severe eosinophilic asthma (SEA) in adults and adolescents aged 12 and above. Clinical Trial and ApprovalFasenra received marketing approval in…
-
Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration includes the establishment of a joint venture (JV) in Beijing aimed at developing and manufacturing novel vaccines for China and emerging markets. Joint Venture DetailsThe JV marks…
-
Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
•
China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio’s innovative Synova platform. Synova Platform and Research FocusThe…
-
AstraZeneca Unveils USD2.5 Billion Beijing R&D Center Plan Amid Strategic China Partnerships
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has announced a five-year plan to invest USD 2.5 billion in establishing its sixth global strategic research and development (R&D) center in Beijing. This initiative is accompanied by multiple major collaborations with domestic Chinese firms, underscoring the company’s commitment to strengthening its foothold in…
-
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
•
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform…
-
Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
•
Japan-based Daiichi Sankyo (TYO: 4568) has announced the launch of Datroway (datopotamab deruxtecan) in Japan. The drug is approved for treating adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer who have undergone prior chemotherapy. First TROP2-Directed Therapy…
-
AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has received approval from the European Union (EU) for its PD-L1 inhibitor Imfinzi (durvalumab) as a monotherapy for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT). Clinical Need and Approval SignificanceSCLC is a highly…
-
AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
•
On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will acquire all outstanding shares of EsoBiotec in a cash and debt-free transaction valued at up to $1 billion. This includes an initial payment of $425 million at…
-
AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered Alteogen Inc. to develop and commercialize subcutaneous versions of an undisclosed cancer drug using Alteogen’s recombinant hyaluronidase enzyme, ALT-B4. This collaboration aims to expand AstraZeneca’s oncology portfolio by leveraging Alteogen’s innovative technology for improved drug…
-
AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
•
UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for a new indication for its PD-L1 inhibitor Imfinzi (durvalumab). The approval allows Imfinzi to be used in combination with chemotherapy for adults with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC), specifically for patients without…
-
AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study
•
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the Phase III DESTINY-Gastric04 study for Enhertu (trastuzumab deruxtecan). The HER2-targeted antibody drug conjugate (ADC) has demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival (OS) in patients with second-line…
-
AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study
•
AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase III WAYPOINT study for their co-developed drug Tezspire (tezepelumab). Tezspire is a thymic stromal lymphopoietin (TSLP) – targeted monoclonal antibody (mAb) that has been approved for severe asthma in over 60 countries worldwide. Study ResultsThe…
-
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III SERENA-6 study for its camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist. Study Details and ResultsThe study evaluated switching to camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor…
-
FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included
•
US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China subsidiary to UK-based AstraZeneca (NASDAQ: AZN) for approximately USD160 million. The deal includes the transfer of all rights to roxadustat, a treatment for anemia caused by chronic kidney disease (CKD), in China. Transaction DetailsUnder the…
-
AstraZeneca Faces Class Action Lawsuits Over China Legal Issues
•
AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States related to recent legal issues in China, including the arrest of its former China market president, Leon Wang. The lawsuits allege that the UK-based pharmaceutical giant made misleading statements about its operations in China, failing…
-
AstraZeneca’s 2024 Financials Beat Expectations with 21% Revenue Growth
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) reported total revenues of USD 54.07 billion in its 2024 financial report, marking a 21% year-on-year (YOY) increase in constant exchange rate terms. Product sales reached USD 50.98 billion, up 19% YOY, with Q4 product sales climbing 19% to USD 13.36 billion. The…
-
FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer
•
The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow…
-
Pfizer Reports 7% Revenue Growth in 2024, Expects Steady Performance in 2025
•
US major Pfizer Inc. (NYSE: PFE) has released its financial results for the fourth quarter and full year of 2024. The company recorded revenues of $63.627 billion for the full year, up 7% year-on-year (YOY) in constant currency terms. Excluding COVID-19 products Paxlovid and Comirnaty, revenues grew by 12%. During…
